ArticleInsights into imaging2026
A nomogram including body composition parameters for predicting recurrence of pT1 clear cell renal cell carcinoma: a multicenter retrospective study.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveTo develop and validate a body composition parameters (BCPs)-based nomogram for predicting recurrence in T1-stage clear cell renal cell carcinoma (ccRCC), comparing its performance with established models while exploring potential biological mechanisms. MATERIALS AND
methods536 patients from three institutions (training cohort: 343, external validation cohort: 193) were included. Univariate and multivariate Cox regression analyses identified independent prognostic factors for recurrence-free survival (RFS), which were incorporated into the nomogram. The model performance was evaluated, and potential biological mechanisms were explored.
resultsThe postoperative nomogram included three independent adverse prognostic factors for RFS: high Leibovich score (HR = 2.18, 95% CI: 1.44-3.31), high visceral adipose tissue density (VATD; HR = 2.34, 95% CI: 1.33-4.12), and high intramuscular adipose tissue content (IMAC; HR = 3.60, 95% CI: 1.29-10.07). The nomogram demonstrated superior discrimination, with a C-index of 0.732 (95% CI: 0.655-0.810) in the training cohort and 0.766 (95% CI: 0.677-0.855) in the validation cohort. The area under the curves (AUCs) for predicting 3- and 5-year RFS were 0.761 and 0.709 (training), and 0.844 and 0.765 (validation), outperforming the TNM, Leibovich, and SSIGN models. Through 5-fold cross-validation within the training cohort, the model achieved mean AUCs of 0.761 (3-year) and 0.683 (5-year). Calibration curves showed good consistency. Decision curve analysis indicated favorable clinical utility. Risk stratification (cutoff = 94.18) based on nomogram scores revealed significant RFS differences. Exploratory in silico analyses of transcriptomic data suggested enrichment in distinct cancer-related and metabolic pathways, as well as varying drug sensitivities between cohorts.
conclusionThe BCPs-based nomogram effectively predicts recurrence of T1 ccRCC and significantly improves upon existing prognostic models. CRITICAL RELEVANCE STATEMENT: The nomogram, combining body composition parameters and Leibovich score, outperformed established prognostic models in predicting T1 ccRCC recurrence, enabling personalized risk stratification. KEY POINTS: Body composition parameters correlate with oncological outcomes in RCC, but remain underexplored in the T1 clear cell subtype. Elevated Leibovich score, visceral adipose tissue density, and intramuscular adipose tissue content independently predicted reduced RFS, linked to cancer-related and metabolic pathways enrichment. The body composition parameters-based nomogram could effectively predict postoperative recurrence in T1 ccRCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.